Background Cancer is a disease of abnormal cell proliferation caused by abnormal expression of cancer-related genes. However, it is still difficult to distinguish benign and malignant lesions in many cases. KIF4A has been reported to be associated with a variety of cancer lesions. We aimed to explore whether KIF4A could be used as a biomarker of pan-cancer diagnostic. Methods We identified twenty-eight cell cycle-related genes that were overexpressed in no less than ten types of cancer. We determined KIF4A mRNA and protein expression in osteosarcoma (OS) cells. Furthermore, to determine the effect of KIF4A in OS, we silenced KIF4A in OS cells and detected cell viability, colony formation, invasion, migration, apoptosis and cell cycle parameters. Results KIF4A exhibited upregulated expression in eleven types of cancer. Cell cycle-related genes are extensively overexpressed in various types of cancers. KIF4A overexpression can serve as a diagnostic and prognostic marker in various cancers. Silencing KIF4A inhibited the viability, colony formation, invasion and migration and induced apoptosis and cell cycle arrest of OS cells. Our findings revealed that high expression of KIF4A could serve as a diagnostic and prognostic marker in OS cancers. Conclusion KIF4A could serve as a pan-cancer diagnostic and prognostic marker. KIF4A could be used as a novel therapeutic target for OS.
Purpose PR loss in ER+/HER2- breast cancer indicates worse prognosis and insensitivity to anti-estrogen therapy, while the mechanisms of PR loss in ER+/HER2- breast cancer remain unrevealed. Methods In this study, ER+/PR+/HER2- and ER+/PR-/HER2- breast cancer cases from TCGA were used. 1387 pathways were analyzed and used as variables for classifying the two groups with LASSO regression. Results ER+/PR+/HER2- and ER+/PR-/HER2- breast cancer groups can be classified by a combination of 13 pathways using their activity score. Among the 13 pathways, those involving growth factors and ion-channel transporters were most significant in the distinction, followed by pathways involving immune modulation and cell metabolism. Two growth factor pathways, EGF and IGF-1, were deferentially regulated in ER+/PR+/HER2- and ER+/PR-/HER2- groups. Conclusions In conclusion, this study indicated in ER+/HER2- breast cancers the various status of PR expression can be an indication of molecular variation, particularly for the growth factor pathway activation.
Background: Cancer is a disease of abnormal cell proliferation that is caused by aberrantly expressed cancer-related genes. Transcriptome analysis to identify differential gene expression between tumors and paring normal tissue can help to reveal the key process of cell proliferation in cancer. Methods: By screening RNA-seq data covering twelve types of cancer and their paring normal tissue from the cancer genome atlas (TCGA), we identified twenty-eight cell-cycle-related genes that were overexpressed in no less than ten types of cancers. Results: Among them, kinesin family member 4A (KIF4A) and stromal tumor infiltrating lymphocyte (STIL) exhibited upregulated expression in eleven types of cancer, making them promising pan-cancer diagnostic markers. The high expression of either KIF4A or STIL indicates poor prognosis in four types of cancer. We further conducted the expression of KIF4A and STIL by immunohistochemistry(IHC) in osteosarcoma(OS) and paring normal tissue samples from a cohort of 57 osteosarcoma patients,which confirmed the results of bioinformatics analysis . Conclusions: KIF4A and STIL can serve as pan-cancer diagnostic and prognostic markers. The fact that they both function in the mitotic chromosome segregation process further emphasizes the importance of mitosis regulation and chromosome stability in carcinogenesis and cancer development.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.